Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
33 Leser
Artikel bewerten:
(0)

Solid Tumor Market (2016-2021): By Type, Drug & Region - Driven by Rapidly Developing Medical Infrastructure in APAC - Research and Markets

DUBLIN, Feb 7, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Solid Tumor Market - Forecast (2016-2021)" report to their offering.

Solid tumors are diagnosed by the formation of a group of abnormal tissues that do not comprise of any cyst or liquid areas within. Solid tumours is classified into two types in medical terms, i.e. benign (non-cancerous) as well as malignant (cancerous) in nature. Solid tumors majorly comprise of lymphomas, carcinomas, sarcomas and melanomas; whereas, all forms of leukemias usually do not cause solid tumor formation.

Hence, most of the solid tumors are treated via radiotherapy, chemotherapy and/or surgery. Chemotherapy is often utilized along with other modes of solid tumor treatment i.e. radiation and/or surgery. Globally increasing instances of solid tumors is expected to drive the demand for solid tumor market during the period of study.

Geographically North America dominated solid tumor market driven by best in class infrastructure, best in industry practices and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest market for solid tumor market. Asia Pacific is projected to have fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China, and India in this region.

Companies Mentioned:

  • AstraZeneca plc
  • Abbott Laboratories, Inc.
  • Amgen, Inc.
  • Biogen Idec, Inc.
  • Boehringer Ingelheim GmbH
  • Baxter International, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Kyowa Hakko Kirin Co., Ltd.
  • Sanofi

Key Topics Covered:

1. Solid Tumor Market - Market Overview
2. Executive Summary
3. Market Landscape
4. Solid Tumor Market- Market Forces
5. Solid Tumor Market- Strategic Analysis
6. Solid Tumor Market, By Type
7. Solid Tumor Market, By Drug
8. Solid Tumor Market, By Geography
9. Solid Tumor Market - Market Entropy
10. Company Profiles
11. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/7pttmp/solid_tumor

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.